Trading Signals: HTBX Stock Price Prediction and Forecast (Mon. Dec. 28, 2015 - Mon. May. 2, 2022)(Heat Biologics, Inc.)
| HTBX latest price $7.2100 (2.85%) ($7.2100 - $7.2300) on Sat. Jun. 19, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 8.6% (three month average) | RSI | 62 | Latest Price | $7.2100(2.85%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | HTBX declines -1.1% a day on average for past five trading days. | Weekly Trend | HTBX advances 3.3% a week on average for past two weeks. | Market Behavior | Normal for large cap. Normal for small cap. | Correlated ETFs | Broad market will support HTBX advance at 0% a week (0% probability) (0%) (0%) (0%) (0%) (0%) | Factors Impacting HTBX price | HTBX will decline at least -4.3% in a week (0% probabilities). (0%) (0%) (0%) (0%) (0%) | | | | | Relative Volatility | | | | Market Trend Strength | -4.3% (StdDev 8.6%) | Hourly BBV | 0 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $7.11(1.41%) | 10 Day Moving Average | $7.43(-2.96%) | 20 Day Moving Average | $6.96(3.59%) | To recent high | -32.9% | To recent low | 23.9% | Market Cap | $N/A | | | | Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC. |